Risk factors
BridgeBio Pharma (BBIO) risk factors
Item 1A of every BridgeBio Pharma, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors88 risks5 new31 dropped29 reworded
BridgeBio highlights commercialization risks for Attruby and Beyonttra, exposure to new federal reference pricing pressures, and royalty monetization covenants.
Filed Feb 24, 2026 - FY2024 10-K risk factors114 risks
BridgeBio's core risks center on clinical trial execution, complex manufacturing of novel gene and protein therapies, and regulatory approvals for rare Mendelian diseases.
Filed Feb 20, 2025